ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)

S. C. Jordan, N. Ammerman, M. Toyoda, S. Ge, E. Huang, A. Peng, S. Sethi, R. Najjar, E. Ortiz, M. Chu, A. De Guzman, I. Kim, K. Lim, J. Choi, A. Vo

Cedars Sinai Medical Ctr, Los Angeles, CA

Meeting: 2020 American Transplant Congress

Abstract number: B-063

Keywords: Antibodies, Highly-sensitized, Kidney transplantation, Rejection

Session Information

Session Name: Poster Session B: Kidney Chronic Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production. Therapeutic options currently available to prevent and treat cABMR are limited. Here, we report our updated, 18 month experience using clazakizumab, a novel IL-6 inhibitor, in HS patients with cABMR + transplant glomerulopathy (TG).

*Methods: Since February 2018, 10 adult patients with biopsy proven cABMR +TG and DSA+ were enrolled in a phase I/II, single-center, open-label exploratory study. All patients received clazakizumab 25 mg subcutaneous injections monthly for 6 doses, underwent a 6-month protocol biopsy, followed by 6 monthly 25 mg doses. After 12 months of therapy, patients were able to enter a long-term extension (LTE) to receive clazakizumab 25 mg subQ every other month. Patients were monitored for DSA relative intensity scores [(RIS); 0 = No DSA; 2 = <5000MFI (weak); 5= 5000-104MFI (moderate);10= >104MFI (strong)], renal function, CRP levels, and T-regulatory (Treg) cell responses.

*Results: Eight patients continue to undergo clazakizumab therapy, 7 of whom have transitioned to LTE dosing (N=5 have undergone 18M of therapy). Two patients were withdrawn from the study to date, 1 patient progressed to graft failure and withdrew after 4M of therapy, 1 patient preferred to return to Tocilizumab (anti-IL6-R) therapy after 7M. All patients showed marked reductions in CRP levels post-clazakizumab (1.11±1.25 at 0M v 0.43±0.17 at 12M, p=0.31). After 12 months, reductions in mean DSA-RIS were sustained (6.40±3.31 historical vs 3.43±4.58 at 12M, p=0.14) and in 5 patients, DSA-RIS remained reduced at 18M (6.40±3.31 vs 2.50±4.18 at 18M, p=0.06); see Figure 1a, for DSA MFI. 100% of patients’ DSAs were class II (DQ, 80%). Mean eGFRs remained stable at 12M (41.90±12.09ml/min at 0M vs. 38.86±10.42ml/min at 12M, p=0.60); and 18M in 5 patients (41.90±12.09ml/min at 0M vs 44±9.51ml/min at 18M, p=0.74); see Figure 1b. Treg cells tended to increase at 12M (2.39±1.02% at 0M vs 3.30±1.13% at 12M, p=0.12). No serious adverse events seen were considered directly related to drug.

*Conclusions: cABMR+TG patients treated with clazakizumab showed stabilization of renal function and improvements in DSA RIS after 18 months of therapy. A larger, controlled study is underway to evaluate the potential benefits of clazakizumab in cABMR treatment.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Jordan SC, Ammerman N, Toyoda M, Ge S, Huang E, Peng A, Sethi S, Najjar R, Ortiz E, Chu M, Guzman ADe, Kim I, Lim K, Choi J, Vo A. Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/clazakizumab-anti-il-6-monoclonal-as-an-agent-to-reduce-donor-specific-hla-antibodies-dsa-and-improve-outcomes-in-patients-with-chronic-active-antibody-mediated-rejection-post-kidney-transplanta/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences